ISPO

Published in Cancer Detection and Prevention 1999; 23(2):172-176.

Subcutaneous Administration of Interleukin-2 and Interferon-α2b in Advanced Renal Cell Carcinoma: Long-Term Results

Maria Cristina Locatelli, M.D.,a Giovanna Facendola, M.D.,a Giorgio Pizzocaro, M.D.,b Luigi Piva, M.D.,b Carlo Pegoraro, M.D.,c Enrico Bobbio Pallavicini, M.D.,d A. Signaroldi, M.D.,e M. Meregalli, M.D.,f Franco Lombardi, M.D.,g Giordano D. Beretta, M.D,,h Franco Scanzi, M.D.,i Roberto Labianca, M.D.,a Giuseppe Dallavalle, M.D.,a and Gino Luporini, M.D.a

a Divisione di Oncologia Medica, Ospedale S. Carlo Borromeo, Milan, Italy; b Divisione di Oncologia Chirurgica Urologica, Istituto Nazionale Tumori, Milan, Italy; c Divisione di Urologia, Ospedale Carlo Poma, Mantua, Italy; d Divisione Medicina, Ospedale Maggiore, Crema; e Servizio di Oncologia Medica, Ospedale Casalpusterlengo; f Divisione Medicina II, Ospedale Santa Corona, Garbagnate Milanese; g Divisione di Oncologia Medica, Magenta; hDivisione di Medicina, Servizio di Oncologia Medica, Ospedale E. Bassini, Cinisello Balsamo; and i Divisione di Oncologia Medica, Ospedale Niguarda, Milan, Italy.

Address all correspondence and reprint requests to: Maria Cristina Locatelli, MD, Division of Medical Oncology, S. Carlo Borromeo Hospital, Via Pio Secondo, 3, 20153 Milan, Italy.

ABSTRACT: Clinical data have supported the combination of subcutaneous r-interleukin-2 (rIL-2) and r-interferon-α (rIFN-α) as a promising combination for advanced renal cell carcinoma (RCC), with a reduced toxicity. We evaluated the activity and safety of this outpatient immunotherapy and report on the clinical results and the long-term survival analysis. Objective responses was observed in 9 of 50 (18%) patients, 6 of whom (12%) achieved a complete response. Overall median survival is 12 months; six patients were surviving at a median follow-up of 24 months, and three (6%) are still progression-free.

KEY WORDS: advanced renal cancer, interleukin-2, interferon-)2b, subcutaneous administration.

For more information, contact sp00471@schering-pl.it

http://www.cancerprev.org/Journal/Issues/23/2/321